Eli Lilly

Study results support BYDUREON’s NDA

Friday, July 8, 2011 12:21 PM

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced results from QT (tQT) study of exenatide to increase the QT interval across a wide range of plasma concentrations. The study was conducted to satisfy a requirement by the FDA in support of the New Drug Application (NDA) for BYDUREON (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

More... »

Lilly pitches plan to overcome key patent losses

Friday, July 8, 2011 10:15 AM

Eli Lilly, only months away from losing patent protection for its top-selling drug, told investors the keys to overcoming this and other patent losses lie in its labs and emerging markets including China, according to Mercury News.

More... »

Former Pfizer research chief wary of R&D strategy

Thursday, July 7, 2011 10:02 AM

Pfizer may have won over shareholders with its recent decision to pare back R&D spending, but it could be shortchanging them in the long run, Pfizer’s former research chief told Reuters.

More... »

CEO says Eli Lilly is committed to R&D

Thursday, June 30, 2011 01:14 PM

Eli Lilly is committed to spending what it takes to come up with innovative drugs over the long term, its chief executive said, even though the company's earnings are expected to tumble over the next three years.

More... »

Lilly and investor group form new critical-care company BioCritica

Monday, May 23, 2011 02:17 PM

Eli Lilly has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica, a newly-formed and privately held biotechnology company. BioCritica, based in Central Indiana, will initially focus on the continued U.S. development and commercialization of Xigris (drotrecogin alfa (activated)), Lilly's medicine for severe sepsis. BioCritica intends to ultimately build a broad portfolio of innovative, hospital-based critical care medicines.

More... »

Astellas adds four to team

Tuesday, May 3, 2011 12:33 PM

Astellas Pharma Global Development, a subsidiary of Tokyo-based Astellas Pharma, welcomes four new industry leaders to its team.

More... »

Boehringer/Lilly's diabetes drug receives FDA approval

Tuesday, May 3, 2011 12:20 PM

Boehringer Ingelheim and its partner Eli Lilly report that the FDA has approved their once-daily type II diabetes pill linagliptin (Tradjenta).

More... »

Immune Design adds Carlos Paya as CEO

Wednesday, April 27, 2011 01:22 PM

Seattle-based vaccine developer Immune Design’s new CEO is Carlos Paya, the former president of Ireland-based biotech Elan. Paya is replacing Immune Design’s founding CEO, Steve Reed, who will continue to serve on the company’s executive management team and board, according to Xconomy Seattle.

More... »

Eli Lilly 's new anti-psychotic offers no weight gain

Wednesday, April 27, 2011 12:49 PM

The schizophrenia drug Zyprexa was one of Eli Lilly's biggest success stories; however, the company has also paid big settlements regarding claims that it hid data about a burdensome weight-gain side effect. As a result, Lilly has begun late-stage trials for a next-generation schizophrenia drug that offers treatment without weight gain, according to FierceBiotech.

More... »

Lilly and Medtronic to collaborate on Parkinson’s research

Tuesday, April 26, 2011 01:11 PM

Eli Lilly and Medtronic will collaborate to research and develop a new approach to treating Parkinson's disease.  The new approach involves investigating the delivery of a new medicine to the brain using an implantable drug delivery system. The goal is to develop a therapeutic approach to treating Parkinson's disease that combines Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

More... »